nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—VEGFA—amyotrophic lateral sclerosis	0.778	1	CbGaD
Gliclazide—Erythropenia—Riluzole—amyotrophic lateral sclerosis	0.0229	0.143	CcSEcCtD
Gliclazide—Fungal skin infection—Riluzole—amyotrophic lateral sclerosis	0.00456	0.0285	CcSEcCtD
Gliclazide—Faecal incontinence—Riluzole—amyotrophic lateral sclerosis	0.00377	0.0236	CcSEcCtD
Gliclazide—Tooth disorder—Riluzole—amyotrophic lateral sclerosis	0.00294	0.0183	CcSEcCtD
Gliclazide—Calculus of kidney—Riluzole—amyotrophic lateral sclerosis	0.00291	0.0181	CcSEcCtD
Gliclazide—Upset stomach—Riluzole—amyotrophic lateral sclerosis	0.00291	0.0181	CcSEcCtD
Gliclazide—Glaucoma—Riluzole—amyotrophic lateral sclerosis	0.00253	0.0158	CcSEcCtD
Gliclazide—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.00245	0.0153	CcSEcCtD
Gliclazide—Nephrolithiasis—Riluzole—amyotrophic lateral sclerosis	0.00237	0.0148	CcSEcCtD
Gliclazide—Glycosuria—Riluzole—amyotrophic lateral sclerosis	0.00235	0.0147	CcSEcCtD
Gliclazide—Delirium—Riluzole—amyotrophic lateral sclerosis	0.00221	0.0138	CcSEcCtD
Gliclazide—Arthropathy—Riluzole—amyotrophic lateral sclerosis	0.00209	0.0131	CcSEcCtD
Gliclazide—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.00205	0.0128	CcSEcCtD
Gliclazide—Gout—Riluzole—amyotrophic lateral sclerosis	0.00204	0.0127	CcSEcCtD
Gliclazide—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.00201	0.0126	CcSEcCtD
Gliclazide—Cataract—Riluzole—amyotrophic lateral sclerosis	0.002	0.0125	CcSEcCtD
Gliclazide—Melaena—Riluzole—amyotrophic lateral sclerosis	0.00186	0.0116	CcSEcCtD
Gliclazide—Coma—Riluzole—amyotrophic lateral sclerosis	0.00174	0.0109	CcSEcCtD
Gliclazide—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00172	0.0108	CcSEcCtD
Gliclazide—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.00165	0.0103	CcSEcCtD
Gliclazide—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00159	0.00992	CcSEcCtD
Gliclazide—Hepatic function abnormal—Riluzole—amyotrophic lateral sclerosis	0.00158	0.00988	CcSEcCtD
Gliclazide—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00983	CcSEcCtD
Gliclazide—Deafness—Riluzole—amyotrophic lateral sclerosis	0.00155	0.00965	CcSEcCtD
Gliclazide—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00154	0.00961	CcSEcCtD
Gliclazide—Injury—Riluzole—amyotrophic lateral sclerosis	0.0015	0.00939	CcSEcCtD
Gliclazide—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00147	0.00919	CcSEcCtD
Gliclazide—Thirst—Riluzole—amyotrophic lateral sclerosis	0.00145	0.00907	CcSEcCtD
Gliclazide—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00888	CcSEcCtD
Gliclazide—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00885	CcSEcCtD
Gliclazide—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00139	0.00867	CcSEcCtD
Gliclazide—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00863	CcSEcCtD
Gliclazide—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00863	CcSEcCtD
Gliclazide—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00863	CcSEcCtD
Gliclazide—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00122	0.00764	CcSEcCtD
Gliclazide—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00751	CcSEcCtD
Gliclazide—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00746	CcSEcCtD
Gliclazide—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00727	CcSEcCtD
Gliclazide—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00718	CcSEcCtD
Gliclazide—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00715	CcSEcCtD
Gliclazide—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00709	CcSEcCtD
Gliclazide—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00687	CcSEcCtD
Gliclazide—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00681	CcSEcCtD
Gliclazide—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00679	CcSEcCtD
Gliclazide—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00669	CcSEcCtD
Gliclazide—Depression—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00663	CcSEcCtD
Gliclazide—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00656	CcSEcCtD
Gliclazide—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00652	CcSEcCtD
Gliclazide—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00652	CcSEcCtD
Gliclazide—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00648	CcSEcCtD
Gliclazide—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00647	CcSEcCtD
Gliclazide—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00638	CcSEcCtD
Gliclazide—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00629	CcSEcCtD
Gliclazide—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.001	0.00627	CcSEcCtD
Gliclazide—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.000999	0.00624	CcSEcCtD
Gliclazide—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.000994	0.00621	CcSEcCtD
Gliclazide—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.000974	0.00608	CcSEcCtD
Gliclazide—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.000959	0.00599	CcSEcCtD
Gliclazide—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.000956	0.00597	CcSEcCtD
Gliclazide—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.000952	0.00594	CcSEcCtD
Gliclazide—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.000949	0.00593	CcSEcCtD
Gliclazide—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.000942	0.00588	CcSEcCtD
Gliclazide—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.000904	0.00565	CcSEcCtD
Gliclazide—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.000894	0.00558	CcSEcCtD
Gliclazide—Chills—Riluzole—amyotrophic lateral sclerosis	0.000858	0.00536	CcSEcCtD
Gliclazide—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.000854	0.00533	CcSEcCtD
Gliclazide—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.000838	0.00523	CcSEcCtD
Gliclazide—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000833	0.0052	CcSEcCtD
Gliclazide—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00082	0.00512	CcSEcCtD
Gliclazide—Tension—Riluzole—amyotrophic lateral sclerosis	0.000817	0.0051	CcSEcCtD
Gliclazide—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.000809	0.00505	CcSEcCtD
Gliclazide—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000805	0.00503	CcSEcCtD
Gliclazide—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00078	0.00487	CcSEcCtD
Gliclazide—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.000772	0.00482	CcSEcCtD
Gliclazide—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000769	0.0048	CcSEcCtD
Gliclazide—Agitation—Riluzole—amyotrophic lateral sclerosis	0.000765	0.00478	CcSEcCtD
Gliclazide—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.000761	0.00475	CcSEcCtD
Gliclazide—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000751	0.00469	CcSEcCtD
Gliclazide—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000745	0.00465	CcSEcCtD
Gliclazide—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.000736	0.00459	CcSEcCtD
Gliclazide—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000732	0.00457	CcSEcCtD
Gliclazide—Cough—Riluzole—amyotrophic lateral sclerosis	0.000726	0.00454	CcSEcCtD
Gliclazide—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.000721	0.0045	CcSEcCtD
Gliclazide—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000719	0.00449	CcSEcCtD
Gliclazide—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000709	0.00443	CcSEcCtD
Gliclazide—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000709	0.00443	CcSEcCtD
Gliclazide—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000709	0.00443	CcSEcCtD
Gliclazide—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.000706	0.00441	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000704	0.0044	CcSEcCtD
Gliclazide—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.0007	0.00437	CcSEcCtD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.000696	0.0112	CbGpPWpGaD
Gliclazide—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000693	0.00433	CcSEcCtD
Gliclazide—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000685	0.00428	CcSEcCtD
Gliclazide—Infection—Riluzole—amyotrophic lateral sclerosis	0.000675	0.00422	CcSEcCtD
Gliclazide—VEGFA—S1P1 pathway—PTGS2—amyotrophic lateral sclerosis	0.000673	0.0108	CbGpPWpGaD
Gliclazide—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000666	0.00416	CcSEcCtD
Gliclazide—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000665	0.00415	CcSEcCtD
Gliclazide—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000663	0.00414	CcSEcCtD
Gliclazide—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00066	0.00412	CcSEcCtD
Gliclazide—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000657	0.0041	CcSEcCtD
Gliclazide—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000635	0.00396	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000619	0.00387	CcSEcCtD
Gliclazide—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000615	0.00384	CcSEcCtD
Gliclazide—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00061	0.00381	CcSEcCtD
Gliclazide—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000606	0.00378	CcSEcCtD
Gliclazide—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000604	0.00377	CcSEcCtD
Gliclazide—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000598	0.00373	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.000592	0.00952	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000587	0.00366	CcSEcCtD
Gliclazide—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000586	0.00366	CcSEcCtD
Gliclazide—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000581	0.00363	CcSEcCtD
Gliclazide—Pain—Riluzole—amyotrophic lateral sclerosis	0.000581	0.00363	CcSEcCtD
Gliclazide—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00056	0.0035	CcSEcCtD
Gliclazide—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000556	0.00347	CcSEcCtD
Gliclazide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.000554	0.00892	CbGpPWpGaD
Gliclazide—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00054	0.00337	CcSEcCtD
Gliclazide—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000537	0.00335	CcSEcCtD
Gliclazide—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000537	0.00335	CcSEcCtD
Gliclazide—VEGFA—SHP2 signaling—BDNF—amyotrophic lateral sclerosis	0.000512	0.00824	CbGpPWpGaD
Gliclazide—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000501	0.00313	CcSEcCtD
Gliclazide—VEGFA—Angiogenesis—MMP9—amyotrophic lateral sclerosis	0.00049	0.00788	CbGpPWpGaD
Gliclazide—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000487	0.00304	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.000483	0.00776	CbGpPWpGaD
Gliclazide—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000481	0.003	CcSEcCtD
Gliclazide—VEGFA—Allograft Rejection—CASP9—amyotrophic lateral sclerosis	0.000474	0.00763	CbGpPWpGaD
Gliclazide—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000465	0.0029	CcSEcCtD
Gliclazide—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000449	0.00281	CcSEcCtD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.000449	0.00721	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.000449	0.00721	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.000449	0.00721	CbGpPWpGaD
Gliclazide—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000432	0.0027	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—TUBA4A—amyotrophic lateral sclerosis	0.000429	0.00691	CbGpPWpGaD
Gliclazide—Rash—Riluzole—amyotrophic lateral sclerosis	0.000428	0.00268	CcSEcCtD
Gliclazide—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000428	0.00267	CcSEcCtD
Gliclazide—Headache—Riluzole—amyotrophic lateral sclerosis	0.000426	0.00266	CcSEcCtD
Gliclazide—VEGFA—Platelet degranulation—SOD1—amyotrophic lateral sclerosis	0.000421	0.00678	CbGpPWpGaD
Gliclazide—ALB—HDL-mediated lipid transport—APOE—amyotrophic lateral sclerosis	0.000419	0.00674	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.000407	0.00654	CbGpPWpGaD
Gliclazide—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000404	0.00252	CcSEcCtD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—SOD1—amyotrophic lateral sclerosis	0.000401	0.00646	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	0.000395	0.00634	CbGpPWpGaD
Gliclazide—VEGFA—Differentiation Pathway—IGF1—amyotrophic lateral sclerosis	0.000387	0.00622	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—PFN1—amyotrophic lateral sclerosis	0.000387	0.00622	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—CD40LG—amyotrophic lateral sclerosis	0.000382	0.00614	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.000375	0.00604	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—GRIA2—amyotrophic lateral sclerosis	0.000364	0.00586	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.000363	0.00583	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—GSR—amyotrophic lateral sclerosis	0.000359	0.00577	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	0.000352	0.00566	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—VCP—amyotrophic lateral sclerosis	0.000346	0.00557	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—TUBA4A—amyotrophic lateral sclerosis	0.000342	0.00549	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—C3—amyotrophic lateral sclerosis	0.000337	0.00543	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—IGF1—amyotrophic lateral sclerosis	0.000332	0.00535	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000332	0.00534	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	0.000332	0.00534	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.000332	0.00533	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—TUBA4A—amyotrophic lateral sclerosis	0.000325	0.00523	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000322	0.00518	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—NEFL—amyotrophic lateral sclerosis	0.000322	0.00517	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.000319	0.00514	CbGpPWpGaD
Gliclazide—VEGFA—Integrins in angiogenesis—IGF1—amyotrophic lateral sclerosis	0.000311	0.005	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.000308	0.00496	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.000308	0.00496	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—PFN1—amyotrophic lateral sclerosis	0.000308	0.00495	CbGpPWpGaD
Gliclazide—VEGFA—Endochondral Ossification—IGF1—amyotrophic lateral sclerosis	0.000307	0.00494	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—GSR—amyotrophic lateral sclerosis	0.000305	0.0049	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000303	0.00487	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000303	0.00487	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—CHAT—amyotrophic lateral sclerosis	0.000299	0.00481	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	0.000299	0.00481	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—ATF1—amyotrophic lateral sclerosis	0.000297	0.00477	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—PFN1—amyotrophic lateral sclerosis	0.000293	0.00471	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—PFN1—amyotrophic lateral sclerosis	0.000285	0.00458	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000283	0.00454	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.000275	0.00442	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—TP53—amyotrophic lateral sclerosis	0.000271	0.00435	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	0.000266	0.00429	CbGpPWpGaD
Gliclazide—VEGFA—Platelet degranulation—IGF1—amyotrophic lateral sclerosis	0.000257	0.00413	CbGpPWpGaD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—IGF1—amyotrophic lateral sclerosis	0.000245	0.00394	CbGpPWpGaD
Gliclazide—ALB—Lipoprotein metabolism—APOE—amyotrophic lateral sclerosis	0.000241	0.00387	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000234	0.00377	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—CASP3—amyotrophic lateral sclerosis	0.000234	0.00376	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000232	0.00373	CbGpPWpGaD
Gliclazide—VEGFA—Endochondral Ossification—MMP9—amyotrophic lateral sclerosis	0.000223	0.00359	CbGpPWpGaD
Gliclazide—CYP2C19—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000222	0.00357	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.000221	0.00356	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—SOD1—amyotrophic lateral sclerosis	0.000213	0.00343	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.000206	0.00331	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—PFN1—amyotrophic lateral sclerosis	0.000203	0.00327	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	0.0002	0.00321	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.000199	0.00321	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000197	0.00317	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000195	0.00314	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000188	0.00303	CbGpPWpGaD
Gliclazide—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—amyotrophic lateral sclerosis	0.000187	0.00301	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000187	0.00301	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000187	0.00301	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	0.000187	0.00301	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000181	0.00292	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000181	0.00292	CbGpPWpGaD
Gliclazide—CYP2C19—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000174	0.0028	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—SOD1—amyotrophic lateral sclerosis	0.000173	0.00279	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000171	0.00275	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	0.000168	0.0027	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000166	0.00267	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000166	0.00267	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000166	0.00267	CbGpPWpGaD
Gliclazide—VEGFA—EPH-Ephrin signaling—MMP9—amyotrophic lateral sclerosis	0.000164	0.00264	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—SOD1—amyotrophic lateral sclerosis	0.000162	0.00261	CbGpPWpGaD
Gliclazide—ALB—Lipid and lipoprotein metabolism—APOE—amyotrophic lateral sclerosis	0.00016	0.00257	CbGpPWpGaD
Gliclazide—CYP2C9—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000159	0.00256	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000159	0.00256	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—GSTP1—amyotrophic lateral sclerosis	0.000158	0.00255	CbGpPWpGaD
Gliclazide—CYP2C19—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000158	0.00254	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—APOE—amyotrophic lateral sclerosis	0.000157	0.00253	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000154	0.00248	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—TUBA4A—amyotrophic lateral sclerosis	0.000152	0.00244	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—TP53—amyotrophic lateral sclerosis	0.00015	0.00241	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000149	0.0024	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—SOD1—amyotrophic lateral sclerosis	0.000149	0.00239	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000148	0.00238	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000145	0.00233	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000144	0.00231	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—SOD1—amyotrophic lateral sclerosis	0.000142	0.00228	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—SOD1—amyotrophic lateral sclerosis	0.000138	0.00222	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PFN1—amyotrophic lateral sclerosis	0.000136	0.00219	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000135	0.00218	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—DAO—amyotrophic lateral sclerosis	0.000135	0.00217	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—DAO—amyotrophic lateral sclerosis	0.000131	0.00211	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—IGF1—amyotrophic lateral sclerosis	0.000129	0.00207	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	0.000128	0.00206	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000124	0.00199	CbGpPWpGaD
Gliclazide—ALB—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000124	0.00199	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000122	0.00195	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000119	0.00191	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000116	0.00186	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000115	0.00185	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	0.000114	0.00183	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.000113	0.00181	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000111	0.00179	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000111	0.00178	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000108	0.00174	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	0.000106	0.00171	CbGpPWpGaD
Gliclazide—ALB—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000105	0.00169	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000103	0.00166	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000102	0.00165	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000101	0.00163	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PLB1—amyotrophic lateral sclerosis	9.93e-05	0.0016	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	9.86e-05	0.00159	CbGpPWpGaD
Gliclazide—CYP2C19—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	9.83e-05	0.00158	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	9.76e-05	0.00157	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	9.72e-05	0.00156	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—SOD1—amyotrophic lateral sclerosis	9.63e-05	0.00155	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GSR—amyotrophic lateral sclerosis	9.46e-05	0.00152	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	9.42e-05	0.00152	CbGpPWpGaD
Gliclazide—ALB—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	9.38e-05	0.00151	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GSR—amyotrophic lateral sclerosis	9.17e-05	0.00147	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—IGF1—amyotrophic lateral sclerosis	9.07e-05	0.00146	CbGpPWpGaD
Gliclazide—CYP2C9—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	8.96e-05	0.00144	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	8.86e-05	0.00142	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	8.64e-05	0.00139	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—amyotrophic lateral sclerosis	8.64e-05	0.00139	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	7.83e-05	0.00126	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	7.81e-05	0.00126	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CHAT—amyotrophic lateral sclerosis	7.76e-05	0.00125	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	7.63e-05	0.00123	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CHAT—amyotrophic lateral sclerosis	7.53e-05	0.00121	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	7.42e-05	0.00119	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	7.36e-05	0.00118	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—RAB5A—amyotrophic lateral sclerosis	7.26e-05	0.00117	CbGpPWpGaD
Gliclazide—CYP2C19—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	7.06e-05	0.00114	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PFN1—amyotrophic lateral sclerosis	7.03e-05	0.00113	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—VCP—amyotrophic lateral sclerosis	6.98e-05	0.00112	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	6.97e-05	0.00112	CbGpPWpGaD
Gliclazide—CYP2C19—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	6.97e-05	0.00112	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	6.76e-05	0.00109	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	6.66e-05	0.00107	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	6.6e-05	0.00106	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	6.44e-05	0.00104	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	6.35e-05	0.00102	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	6.32e-05	0.00102	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	6.29e-05	0.00101	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—MMP9—amyotrophic lateral sclerosis	6.1e-05	0.000982	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	6.07e-05	0.000976	CbGpPWpGaD
Gliclazide—ALB—Metabolism—VAPB—amyotrophic lateral sclerosis	6.03e-05	0.00097	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TPK1—amyotrophic lateral sclerosis	6.03e-05	0.00097	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	6e-05	0.000965	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	5.93e-05	0.000954	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—VEGFA—amyotrophic lateral sclerosis	5.92e-05	0.000953	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	5.92e-05	0.000952	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—IGF1—amyotrophic lateral sclerosis	5.88e-05	0.000945	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—amyotrophic lateral sclerosis	5.64e-05	0.000908	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	5.62e-05	0.000904	CbGpPWpGaD
Gliclazide—ALB—Metabolism—VAPA—amyotrophic lateral sclerosis	5.51e-05	0.000887	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—VAPB—amyotrophic lateral sclerosis	5.41e-05	0.00087	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TPK1—amyotrophic lateral sclerosis	5.41e-05	0.00087	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	5.35e-05	0.00086	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	5.35e-05	0.00086	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—TP53—amyotrophic lateral sclerosis	5.22e-05	0.00084	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.13e-05	0.000824	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	5.05e-05	0.000812	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—VAPA—amyotrophic lateral sclerosis	4.95e-05	0.000796	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	4.93e-05	0.000794	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	4.93e-05	0.000794	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—TP53—amyotrophic lateral sclerosis	4.88e-05	0.000785	CbGpPWpGaD
Gliclazide—ALB—Metabolism—FIG4—amyotrophic lateral sclerosis	4.82e-05	0.000775	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	4.76e-05	0.000766	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.6e-05	0.00074	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	4.6e-05	0.00074	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	4.51e-05	0.000726	CbGpPWpGaD
Gliclazide—ALB—Metabolism—DAO—amyotrophic lateral sclerosis	4.36e-05	0.000701	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MMP9—amyotrophic lateral sclerosis	4.36e-05	0.000701	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—FIG4—amyotrophic lateral sclerosis	4.33e-05	0.000696	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.2e-05	0.000675	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.17e-05	0.000671	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	4.08e-05	0.000655	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.05e-05	0.000651	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	4.02e-05	0.000647	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	3.95e-05	0.000634	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—DAO—amyotrophic lateral sclerosis	3.91e-05	0.000629	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.83e-05	0.000617	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	3.82e-05	0.000615	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.72e-05	0.000598	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	3.64e-05	0.000585	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	3.57e-05	0.000574	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SOD1—amyotrophic lateral sclerosis	3.4e-05	0.000547	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PLB1—amyotrophic lateral sclerosis	3.3e-05	0.000531	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—APOE—amyotrophic lateral sclerosis	3.16e-05	0.000507	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.12e-05	0.000501	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—APOE—amyotrophic lateral sclerosis	3.06e-05	0.000492	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	3.05e-05	0.00049	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSR—amyotrophic lateral sclerosis	3.05e-05	0.00049	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	2.97e-05	0.000477	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.93e-05	0.000471	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TP53—amyotrophic lateral sclerosis	2.9e-05	0.000466	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.78e-05	0.000447	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	2.74e-05	0.00044	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	2.7e-05	0.000435	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	2.63e-05	0.000423	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—C3—amyotrophic lateral sclerosis	2.59e-05	0.000416	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CHAT—amyotrophic lateral sclerosis	2.5e-05	0.000403	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	2.5e-05	0.000401	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.49e-05	0.000401	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.41e-05	0.000388	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.28e-05	0.000367	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.27e-05	0.000365	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	2.25e-05	0.000361	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.16e-05	0.000348	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.1e-05	0.000337	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IGF1—amyotrophic lateral sclerosis	2.07e-05	0.000333	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.05e-05	0.00033	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	2.05e-05	0.00033	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.99e-05	0.00032	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.87e-05	0.000301	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.57e-05	0.000252	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.53e-05	0.000247	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.45e-05	0.000233	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.41e-05	0.000226	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.35e-05	0.000218	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.35e-05	0.000216	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.28e-05	0.000206	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.24e-05	0.000199	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.21e-05	0.000194	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.11e-05	0.000179	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.1e-05	0.000177	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—amyotrophic lateral sclerosis	1.02e-05	0.000165	CbGpPWpGaD
Gliclazide—ALB—Metabolism—APOE—amyotrophic lateral sclerosis	1.02e-05	0.000164	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.01e-05	0.000163	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—amyotrophic lateral sclerosis	9.83e-06	0.000158	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	9.13e-06	0.000147	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	8.33e-06	0.000134	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.97e-06	0.000112	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.26e-06	0.000101	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.71e-06	9.18e-05	CbGpPWpGaD
